These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 24092875)

  • 1. Reclassification of European patients' cardiovascular risk using the updated Systematic Coronary Risk Evaluation algorithm.
    Halcox JP; Tubach F; Sazova O; Sweet S; Medina J;
    Eur J Prev Cardiol; 2015 Feb; 22(2):200-2. PubMed ID: 24092875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum uric acid levels are associated with cardiovascular risk score: A post hoc analysis of the EURIKA study.
    Borghi C; Rodriguez-Artalejo F; De Backer G; Dallongeville J; Medina J; Nuevo J; Guallar E; Perk J; Banegas JR; Tubach F; Roy C; Halcox JP
    Int J Cardiol; 2018 Feb; 253():167-173. PubMed ID: 29306459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-reactive protein levels in patients at cardiovascular risk: EURIKA study.
    Halcox JP; Roy C; Tubach F; Banegas JR; Dallongeville J; De Backer G; Guallar E; Sazova O; Medina J; Perk J; Steg PG; Rodríguez-Artalejo F; Borghi C
    BMC Cardiovasc Disord; 2014 Feb; 14():25. PubMed ID: 24564178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How much does HDL cholesterol add to risk estimation? A report from the SCORE Investigators.
    Cooney MT; Dudina A; De Bacquer D; Fitzgerald A; Conroy R; Sans S; Menotti A; De Backer G; Jousilahti P; Keil U; Thomsen T; Whincup P; Graham I;
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):304-14. PubMed ID: 19609139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
    Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
    Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New European guidelines for the management of dyslipidaemia in cardiovascular prevention].
    Descamps OS; De Backer G; Annemans L; Muls E; Scheen AJ; ;
    Rev Med Liege; 2012 Mar; 67(3):118-27. PubMed ID: 22611827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ten years cardiovascular risk estimation according to Framingham score and non HDL-cholesterol in blood donors.
    Graffigna MN; Berg G; Migliano M; Salgado P; Soutelo J; Musso C
    Diabetes Metab Syndr; 2015; 9(1):24-7. PubMed ID: 25470632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dyslipidemia therapy update: the importance of full lipid profile assessment.
    Menown IB; Murtagh G; Maher V; Cooney MT; Graham IM; Tomkin G
    Adv Ther; 2009 Jul; 26(7):711-8. PubMed ID: 19649582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of using different SCORE tables for estimating cardiovascular risk.
    Brotons C; Moral I; Soriano N; Cuixart L; Osorio D; Bottaro D; Puig M; Joaniquet X; Marcos A; Casasa A
    Rev Esp Cardiol (Engl Ed); 2014 Feb; 67(2):94-100. PubMed ID: 24795115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms associated with cholesterol and risk of cardiovascular events.
    Kathiresan S; Melander O; Anevski D; Guiducci C; Burtt NP; Roos C; Hirschhorn JN; Berglund G; Hedblad B; Groop L; Altshuler DM; Newton-Cheh C; Orho-Melander M
    N Engl J Med; 2008 Mar; 358(12):1240-9. PubMed ID: 18354102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Italian cardiovascular mortality charts of the CUORE Project: are they comparable with the SCORE charts?].
    Donfrancesco C; Palmieri L; Vanuzzo D; Panico S; Cesana G; Ferrario M; Pilotto L; Giampaoli S;
    G Ital Cardiol (Rome); 2010 Feb; 11(2):148-53. PubMed ID: 20408479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of the triglyceride to high-density lipoprotein cholesterol ratio for predicting mortality risk in type 2 diabetes: role of kidney dysfunction.
    Zoppini G; Targher G; Negri C; Stoico V; Gemma ML; Bonora E
    Atherosclerosis; 2010 Sep; 212(1):287-91. PubMed ID: 20510417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The systematic coronary risk evaluation (SCORE) for the prevention of cardiovascular diseases. Does evidence exist for its effectiveness? A systematic review.
    Tomasik T; Krzysztoń J; Dubas-Jakóbczyk K; Kijowska V; Windak A
    Acta Cardiol; 2017 Aug; 72(4):370-379. PubMed ID: 28705107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease.
    Pekkanen J; Linn S; Heiss G; Suchindran CM; Leon A; Rifkind BM; Tyroler HA
    N Engl J Med; 1990 Jun; 322(24):1700-7. PubMed ID: 2342536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-high-density lipoprotein cholesterol in secondary prevention of coronary artery disease: a unique risk factor or redundant information?
    Holcombe SM; Brubaker PH
    J Cardiopulm Rehabil Prev; 2007; 27(6):386-9. PubMed ID: 18197073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease.
    Nishizawa Y; Shoji T; Kakiya R; Tsujimoto Y; Tabata T; Ishimura E; Nakatani T; Miki T; Inaba M
    Kidney Int Suppl; 2003 May; (84):S117-20. PubMed ID: 12694324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. The EURIKA study.
    Banegas JR; López-García E; Dallongeville J; Guallar E; Halcox JP; Borghi C; Massó-González EL; Sazova O; Perk J; Steg PG; De Backer G; Rodríguez-Artalejo F
    Int J Cardiol; 2013 Jun; 166(1):210-4. PubMed ID: 22056474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication.
    van de Woestijne AP; van der Graaf Y; Liem AH; Cramer MJ; Westerink J; Visseren FL;
    J Am Coll Cardiol; 2013 Nov; 62(20):1834-41. PubMed ID: 23948286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.